Microparticle-delivered therapy likely to be the first step toward stopping autoimmune diseases

According to the federal government's National Institute of Neurological Disorders and Stroke, nearly 3 million people worldwide -; with almost a third in the United States -; are living with multiple sclerosis (MS), a disabling neurological disease in which the body's immune system mistakenly attacks nerves feeding information to the central nervous system (the brain and spinal cord). Although rarely fatal, MS can lead to long-term disabilities, and impair movement, muscle control, vision and cognition.

Related Keywords

United States ,Jamie Spangler ,Kelly Rhodes ,Stephany Tzeng ,Giorgio Raimondi ,Derek Vandyke ,Sarah Neshat ,Dongwoo Lee ,Megan Craig ,Shirley Lowmaster ,Marcos Iglesias ,National Institutes Of Health ,Johns Hopkins Bloomberg School Of Public Health ,Johns Hopkins University ,Vascularized Composite Allotransplantation Research Laboratory ,Department Of Defense ,Johns Hopkins University School Of Medicine ,Spangler Lab ,Johns Hopkins University Whiting School Of Engineering ,National Institute Of Neurological Disorders ,Drug Delivery Laboratory ,School Of Medicine ,National Institute ,Neurological Disorders ,Johns Hopkins Medicine ,Johns Hopkins University School ,Assistant Professor ,Reconstructive Surgery ,Johns Hopkins ,Jordan Green ,Johns Hopkins University Whiting School ,Johns Hopkins Bloomberg School ,Public Health ,Sidney Kimmel Comprehensive Cancer Center ,Kaitlyn Storm ,National Institutes ,Multiple Sclerosis ,Clerosis ,Rain ,D4 ,Fell ,Central Nervous System ,Immune System ,Laboratory ,Medicine ,Microparticles ,Muscle ,Myelin ,Nerve ,Nervous System ,Neurological Disease ,Mh ,Stroke ,